Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ophtha.2014.03.029 http://scihub22266oqcxt.onion/10.1016/j.ophtha.2014.03.029 C4145013!4145013!24835758     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24835758.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Ophthalmology 2014 ; 121 (9): 1720-6 Nephropedia Template TP {{tp|p=24835758|t=2014. Cost Evaluation of Surgical and Pharmaceutical Options in Treatment for Vitreomacular Adhesions and Macular Holes |pdf=|usr=}}{{24835758}} gab.com Text Cost Evaluation of Surgical and Pharmaceutical Options in Treatment for Vitreomacular Adhesions and Macular Holes JO: Ophthalmology http://www.kidney.de/pget.php?&tw=1&pmid=24835758 #FOAvip Objective: To evaluate cost-effectiveness and cost utilities for treatment options for vitreomacular adhesions (VMA) and full thickness macular holes (MH). Design: A Markov model of cost-effectiveness and utility. Participants: There were no participants. Methods: Outcomes of published clinical trials (index studies) of surgical treatment of VMA and MH, and a prospective, multicenter clinical trial of pharmaceutical vitreolysis with intravitreal ocriplasmin with saline control were used to generate a model for costs of treatment and visual benefits. All techniques were assumed to result in a 2.5 line visual benefit if anatomy was resolved. Markov analysis, with cost data from the Center of Medicare and Medicaid Services (CMS), was used to calculate imputed costs for each primary treatment modality in a facility setting with surgery performed in a hospital serving as the highest end of the range and non-facility setting with surgery performed in an ambulatory surgery center (ASC) serving as the lowest end of the range. Main Outcome Measures: Imputed costs of therapy, cost per line saved, cost per line-year saved, cost per quality-adjusted life years (QALY). Results: When PPV was selected as the primary procedure, the overall imputed cost ranged from $5,802-$7,931. The cost per line was $2,368-$3,237, the cost per line-year saved was $163-$233 and the cost per QALY was $5,444-$7,442. If intravitreal injection of ocriplasmin (IVO) was the primary procedure, the overall imputed cost was $8,767-$10,977. The cost per line ranged from $3,549-$4,456, the cost per line-year saved was $245-$307, and the cost per QALY was between $8,159-$10,244. If intravitreal saline injection (IVS) were used as a primary procedure, the overall imputed cost was $5,828-8,098. The cost per line was $2,374-3,299, the cost per line-year saved was $164-227 and the cost per QALY was $5,458-7,583. Conclusions: PPV as a primary procedure was the most cost-effective therapy in this model. The other treatments had similar costs per QALY saved, and compare favorably to costs of therapy for other retinal diseases. Twit Text FOAVip Cost Evaluation of Surgical and Pharmaceutical Options in Treatment for Vitreomacular Adhesions and Macular Holes ????Ophthalmology http://www.kidney.de/pget.php?&tw=1&pmid=24835758 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24835758 #FOAvip English Wikipedia <ref>{{Cite pmid|24835758}}</ref> Cost Evaluation of Surgical and Pharmaceutical Options in Treatment for Vitreomacular Adhesions and Macular Holes #MMPMID24835758 Chang JS; Smiddy WE Ophthalmology 2014[Sep]; 121 (9): 1720-6 PMID24835758show ga Objective: To evaluate cost-effectiveness and cost utilities for treatment options for vitreomacular adhesions (VMA) and full thickness macular holes (MH). Design: A Markov model of cost-effectiveness and utility. Participants: There were no participants. Methods: Outcomes of published clinical trials (index studies) of surgical treatment of VMA and MH, and a prospective, multicenter clinical trial of pharmaceutical vitreolysis with intravitreal ocriplasmin with saline control were used to generate a model for costs of treatment and visual benefits. All techniques were assumed to result in a 2.5 line visual benefit if anatomy was resolved. Markov analysis, with cost data from the Center of Medicare and Medicaid Services (CMS), was used to calculate imputed costs for each primary treatment modality in a facility setting with surgery performed in a hospital serving as the highest end of the range and non-facility setting with surgery performed in an ambulatory surgery center (ASC) serving as the lowest end of the range. Main Outcome Measures: Imputed costs of therapy, cost per line saved, cost per line-year saved, cost per quality-adjusted life years (QALY). Results: When PPV was selected as the primary procedure, the overall imputed cost ranged from $5,802-$7,931. The cost per line was $2,368-$3,237, the cost per line-year saved was $163-$233 and the cost per QALY was $5,444-$7,442. If intravitreal injection of ocriplasmin (IVO) was the primary procedure, the overall imputed cost was $8,767-$10,977. The cost per line ranged from $3,549-$4,456, the cost per line-year saved was $245-$307, and the cost per QALY was between $8,159-$10,244. If intravitreal saline injection (IVS) were used as a primary procedure, the overall imputed cost was $5,828-8,098. The cost per line was $2,374-3,299, the cost per line-year saved was $164-227 and the cost per QALY was $5,458-7,583. Conclusions: PPV as a primary procedure was the most cost-effective therapy in this model. The other treatments had similar costs per QALY saved, and compare favorably to costs of therapy for other retinal diseases. äCost Evaluation of Surgical and Pharmaceutical Options in Treatment fo(epmc).pdf DeepDyve Pubget Overpricing